These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

5973 related items for PubMed ID: 3142086

  • 1. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site.
    Dodd I, Nunn B, Robinson JH.
    Thromb Haemost; 1988 Jun 16; 59(3):523-8. PubMed ID: 3142086
    [Abstract] [Full Text] [Related]

  • 2. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator.
    Dodd I, Fears R, Robinson JH.
    Thromb Haemost; 1986 Feb 28; 55(1):94-7. PubMed ID: 3085269
    [Abstract] [Full Text] [Related]

  • 3. The use of active centre acylation to control the pharmacokinetic profile of a recombinant chimaeric plasminogen activator.
    Wilson S, Cronk DW, Dodd I, Esmail AF, Kalindjian SB, McMurdo L, Browne MJ, Smith RA, Robinson JH.
    Thromb Haemost; 1993 Dec 20; 70(6):984-8. PubMed ID: 8165622
    [Abstract] [Full Text] [Related]

  • 4. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
    Bijnens AP, Knockaert I, Cousin E, Kruithof EK, Declerck PJ.
    Thromb Haemost; 1997 Feb 20; 77(2):350-6. PubMed ID: 9157595
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR, van den Berg BM, Moestrup SK, Pannekoek H, van Zonneveld AJ.
    Thromb Haemost; 1998 Nov 20; 80(5):822-8. PubMed ID: 9843178
    [Abstract] [Full Text] [Related]

  • 6. [Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites].
    Zhu MC, Zhan Z, Wang YJ, Liu CG, Shi Y, Cai Q.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep 20; 21(5):565-9. PubMed ID: 16143058
    [Abstract] [Full Text] [Related]

  • 7. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.
    Lamba D, Bauer M, Huber R, Fischer S, Rudolph R, Kohnert U, Bode W.
    J Mol Biol; 1996 Apr 26; 258(1):117-35. PubMed ID: 8613982
    [Abstract] [Full Text] [Related]

  • 8. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 9. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    Thromb Haemost; 1988 Oct 31; 60(2):247-50. PubMed ID: 3146141
    [Abstract] [Full Text] [Related]

  • 10. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
    Yahara H, Matsumoto K, Maruyama H, Nagaoka T, Ikenaka Y, Yajima K, Fukao H, Ueshima S, Matsuo O.
    Thromb Haemost; 1994 Dec 31; 72(6):893-9. PubMed ID: 7740460
    [Abstract] [Full Text] [Related]

  • 11. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells.
    Rijken DC, Emeis JJ, Gerwig GJ.
    Thromb Haemost; 1985 Dec 17; 54(4):788-91. PubMed ID: 3937276
    [Abstract] [Full Text] [Related]

  • 12. Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.
    Einarsson M, Hggroth L, Mattsson C.
    Thromb Haemost; 1989 Dec 29; 62(4):1088-93. PubMed ID: 2515604
    [Abstract] [Full Text] [Related]

  • 13. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology.
    Browne MJ, Dodd I, Carey JE, Chapman CG, Robinson JH.
    Thromb Haemost; 1985 Aug 30; 54(2):422-4. PubMed ID: 3936214
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 17. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.
    Tanswell P, Heinzel G, Greischel A, Krause J.
    J Pharmacol Exp Ther; 1990 Oct 02; 255(1):318-24. PubMed ID: 2120422
    [Abstract] [Full Text] [Related]

  • 18. Identification of t-PA as the major active plasminogen activator in human milk.
    Marshall JM, Rees MC, Cederholm-Williams SA.
    Thromb Haemost; 1986 Apr 30; 55(2):279-81. PubMed ID: 3087004
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
    Hagège J, Delarue F, Peraldi MN, Sraer JD, Rondeau E.
    Lab Invest; 1994 Dec 30; 71(6):828-37. PubMed ID: 7807964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 299.